血友病基因治療市場：依血友病類型及地區分類

Hemophilia Gene Therapy Market, By Hemophilia Type (Hemophilia A, Hemophilia B), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

出版日期: 2026年02月13日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年血友病基因治療市場規模為14.08億美元，預計2033年將達到176.84億美元。預計2026年至2033年，該市場將以43.6%的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	14.08億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	43.60%	預計金額（2033 年）	176.84億美元

血友病是一種遺傳性出血性疾病，其特徵是體內凝血因子缺乏或水平過低。約有13種凝血因子與血小板協同作用，啟動凝血過程。血友病分為三種：A型、B型和C型。 AA型血友病最為常見，由凝血因子VIII缺乏所引起。 BB型血友病由凝血因子IX缺乏所引起，C型血友病由凝血因子XI缺乏所引起。目前的治療方法無法治癒血友病，只能緩解肌肉和關節自發性出血以及顱內出血風險增加等症狀。這些治療方法僅能維持一天的療效，而且費用昂貴。與傳統的凝血因子替代療法相比，基因療法有望透過糾正患者體內編碼凝血因子 VIII 或 IX 的缺陷基因序列（F8 或 F9 基因）來為血友病提供持久的治癒。

在這種治療方法中，重組腺結合病毒最常用於將經過密碼子最佳化的凝血因子（VIII 或 IX）基因遞送至血友病患者體內。該基因透過刪除特定片段進行縮短，以確保編碼序列能夠被病毒載體正確整合。研究觀察到基因表現量呈現劑量依賴性，這意味著隨著基因治療劑量的增加，凝血因子的基因表現也會升高。

市場動態

美國食品藥物管理局（FDA）等監管機構透過授予「突破性療法認定」來支持基因治療產品的研發，該認定適用於正在進行臨床實驗的基因療法。例如，2017年，美國FDA授予baroctocogene roxaparvovec“突破性療法認定”，這是一種使用5型腺結合病毒（AAV5）的VIII因子載體，旨在恢復A型血友病患者的血漿VIII因子水平。

本報告的主要特點

本報告對全球血友病基因治療市場進行了詳細分析，包括預測期（2026-2033 年）的市場規模和複合年成長率，以 2025 年為基準年。
此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本節根據以下參數介紹全球血友病基因治療市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球血友病基因治療市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球血友病基因治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第6章競爭情勢

市佔率分析
公司簡介
- BioMarin Pharmaceuticals, Inc.
- Spark Therapeutics
- Pfizer, Inc.
- UniQure NV
- Ultragenyx Pharmaceutical
- Shire PLC
- Sangamo Therapeutics, Inc
- Freeline Therapeutics

第7章

參考
分析方法

簡介目錄

Product Code: CMI2480

Hemophilia Gene Therapy Market is estimated to be valued at USD 1,408 Mn in 2026 and is expected to reach USD 17,684 Mn by 2033, growing at a compound annual growth rate (CAGR) of 43.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,408 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	43.60%	2033 Value Projection:	USD 17,684 Mn

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins called clotting factors. There are around 13 types of clotting factors that work with blood platelets, which are necessary for clotting process to initiate. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in clotting factor VIII. Hemophilia B occurs due to deficiency of clotting factor IX and Hemophilia C is caused due to clotting factor XI deficiency. Hemophilia is incurable with current therapeutic options, which only reduces symptoms such as spontaneous bleeding in muscles and joints as well as increased risk for intracranial hemorrhage. These treatment options lasts only for a day and is costly. As against conventional clotting factor replacement therapy, gene therapy is expected to offer sustainable cure for hemophilia by correcting defective gene sequence (F8 or F9 gene) that codes for clotting factor VIII or IX in the patient's body.

In this therapy, recombinant Adeno - associated virus is most commonly utilized to deliver a codon optimized version of the clotting factors genes (VIII or IX) to patients affected by hemophilia. This gene is shortened by deleting a discrete portion of the gene to better fit the coding sequence into the viral vector. There is dose dependent gene expression level observed which means genetic expression for clotting factor increases with increased dose of gene therapy.

Market Dynamics

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) are supporting the product development for gene therapy by allotting breakthrough designation status to investigational gene therapy. For instance, in 2017, the U.S. FDA granted breakthrough therapy designation to valoctocogene roxaparvovec, which is an Adeno -associated virus 5 factor VIII vector designed to restore factor VIII plasma concentrations in patients with hemophilia A.

Key features of the study

This report provides an in-depth analysis of the global hemophilia gene therapy market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemophilia gene therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire, Sangamo Therapeutics, Inc., and Freeline Therapeutics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global hemophilia gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemophilia gene therapy market

Market Segmentation

Hemophilia Type Insights (Revenue, USD Mn, 2026 - 2033)
- Hemophilia A
- Hemophilia B
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- BioMarin Pharmaceuticals, Inc.
- Spark Therapeutics
- Pfizer, Inc.
- UniQure NV
- Ultragenyx Pharmaceutical
- Shire
- Sangamo Therapeutics Inc.
- Freeline Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Hemophilia Type
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
Primary Research Respondents View About Market
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
PEST Analysis
Epidemiological Data

4. Global Hemophilia Gene Therapy Market, By Hemophilia Type, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hemophilia A
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hemophilia B
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Hemophilia Gene Therapy Market, By Region, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

6. Competitive Landscape

Market Share Analysis
Company Profiles
- BioMarin Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Spark Therapeutics
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- UniQure NV
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Ultragenyx Pharmaceutical
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Shire PLC
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Sangamo Therapeutics, Inc
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Freeline Therapeutics
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
  - Analyst Views